{"entity":{"id":"chm-029","kind":"drug","name":"CHM-029","aka":[],"tldr":"CHM-029 is an experimental small molecule from CHARM Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia with NPM1 mutation, KMT2A rearrangement or NUP98 rearrangement.","summary":"CHM-029 is a small molecule (oral) from CHARM Therapeutics. A menin inhibitor designed to closely mimic the binding of KMT2A to menin; the company reports preclinical activity against all publicly described menin resistance mutations. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia with NPM1 mutation, KMT2A rearrangement or NUP98 rearrangement. ClinicalTrials.gov registers it in one study linked below. CHARM calls the trial phase 1/2; ClinicalTrials.gov registers NCT07751991 as phase 1, recruiting. The company announced on 7 October 2026 that dosing had begun and that it expects initial data in 2027. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"CHARM Therapeutics: charmtx.com","url":"https://charmtx.com/charm-therapeutics-announces-first-patient-dosed-and-first-cohort-fully-enrolled-in-its-phase-i-ii-clinical-trial-of-chm-029-for-aml/"},{"label":"CHARM Therapeutics: charmtx.com","url":"https://charmtx.com/charm-therapeutics-announces-first-patient-dosed-and-first-cohort-fully-enrolled-in-its-phase-i-ii-clinical-trial-of-chm-029-for-aml/"},{"label":"CHARM Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07751991"},{"label":"ClinicalTrials.gov: trials of CHM-029","url":"https://clinicaltrials.gov/search?intr=CHM-029"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["menin"],"drugs":[],"companies":["charm-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07751991"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CHM-029","modality":"Small molecule (oral)","mechanism":"A menin inhibitor designed to closely mimic the binding of KMT2A to menin; the company reports preclinical activity against all publicly described menin resistance mutations.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/chm-029/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/"}],"company":[{"id":"charm-therapeutics","kind":"company","name":"CHARM Therapeutics","route":"/companies/charm-therapeutics/"}],"trial":[{"id":"nct07751991","kind":"trial","name":"A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML","route":"/trials/nct07751991/"}]}}